tirzepatide cardiovascular outcome trial outcomes An Observational Study of of vs Glucagon-Like Peptide-1 Receptor Agonists In patients with type 2 – Cardiovascular outcomes of semaglutide and

It should not be used in people with type 1 diabetes or for the treatment of diabetic ketoacidosis

It encourages glucose-dependent insulin release, meaning insulin is secreted in response to rising blood sugar and tapers as levels normalize, and it reduces the livers output of excess glucose

PubMed , Journal of Clinical Medicine , vol

Am Rev Respir Dis 1991

For easier dosing calculations, many practitioners use: 2 mg vial + 2 mL bacteriostatic water = 1 mg/mL (1,000 mcg/mL) 5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL (2,500 mcg/mL) Step 3: Draw Bacteriostatic Water Clean the rubber stopper of the bacteriostatic water vial with an alcohol prep pad

Woodward, E